Percheron Therapeutics Limited has released a press release.
EC grants Orphan Drug Designation for ATL1102 in DMD
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Receipt of R&D Tax Incentive payment
- ANP raises A$7.3 million from Oversubscribed Placement
- ANP to apply for dual listing on Frankfurt Stock Exchange
- ANP receives US FDA ODD for ATL1102 in DMD
- Pause in Trading
Later from Percheron Therapeutics
- Annual General Meeting Chairmans Address
- Quarterly Update and Appendix 4C
- ANP meeting with US FDA granted for ATL1102 in DMD
- Half Yearly Report and Half Year Accounts
- ATL1102 DMD Paediatric Investigation Plan submitted to EMA
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics